A new study published in the journal Pharmaceutics suggests that cannabidiol (CBD) may offer relief for people suffering from temporomandibular disorders (TMDs)—a group of conditions causing pain and dysfunction in the jaw joint and surrounding muscles.
Researchers from the Medical University of Silesia in Poland conducted a comprehensive review of studies from 2007 to 2024, analyzing CBD’s potential role in managing TMD symptoms. Their findings highlight CBD’s ability to reduce pain, inflammation, and muscle tension through its interactions with the body’s endocannabinoid system.
According to the study, CBD appears to work by modulating CB1 and CB2 receptors, which are part of the endocannabinoid system responsible for regulating pain and inflammation. It also reduces the release of pro-inflammatory cytokines and affects neurotransmitter pathways involved in pain perception.
Current treatments for TMDs—including physical therapy, medications, and surgery—vary in effectiveness and often come with side effects. The researchers suggest that CBD, known for its anti-inflammatory, analgesic, and anxiolytic (anxiety-reducing) properties, could serve as a safer alternative or complementary therapy.
“CBD demonstrates promise as a potential adjunctive treatment for TMD”, concludes the study. “Further research, including well-designed clinical trials, is necessary to establish its efficacy, optimal dosage, and long-term safety.”
